Shield Therapeutics PLC Composition of Matter Patent Granted on Feraccru® (1655J)

TIDMSTX TIDMSTXW

RNS Number : 1655J

Shield Therapeutics PLC

07 September 2016

Shield Therapeutics plc

("Shield" or the "Company")

Composition of Matter Patent Granted on Feraccru(R)

New patent adds significant protection to Feraccru(R) and extends exclusivity until at least 2034

London, UK, 07 September 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, is pleased to announce that the UK Intellectual Property Office (UKIPO) has granted a composition of matter patent protecting the Company's lead product Feraccru(R), which received marketing authorisation across Europe in February 2016 for the treatment of adults with Iron Deficiency Anaemia in patients with inflammatory bowel disease. Feraccru(R) is currently in the early stages of commercialisation in Europe, having been launched in the UK in June 2016.

UK Patent GB2531742 is entitled "Polymorphs of Ferric Maltol" and significantly expands Feraccru's intellectual property portfolio by protecting the active substance of Feraccru(R) through to at least 2034. Prior to this grant, Feraccru(R) intellectual property rights were based on manufacturing and use patents initially through to 2023 before the application of any patent extensions granted following marketing authorisations, for example a Supplementary Protection Certificate in the European Economic Area.

Carl Sterritt, Founder and Chief Executive Officer, commented: "I am delighted that such a highly regarded body as the UKIPO has granted Shield a composition of matter claim to the active substance in Feraccru(R). In doing so, this has significantly added to the breadth of the IP for Feraccru(R) as well as providing a lengthy extension to that protection. Allowance at the UKIPO is an indicator of the protection that we are anticipating in other territories when the national phase is entered in April 2017. Shield intends to seek protection across a broad range of geographies at that time, and such composition of matter protection should enable Shield to prevent third parties from manufacturing or selling the product for any use until at least 2034."

- Ends -

For further information please contact:

 
 Shield Therapeutics plc                [phone] 
 Carl Sterritt, Chief Executive 
  Officer 
  Richard Jones, Chief Financial 
  Officer 
 
 NOMAD 
  Liberum Capital Limited 
  Christopher Britton 
  Steve Pearce                          [phone] 
 Financial PR Advisor                   [phone] 
  Consilium Strategic Communications     [e-mail] 
 Mary-Jane Elliott 
  Matthew Neal 
  Lindsey Neville 
  Hendrik Thys 
 

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Company has a marketed product, Feraccru(R), for the treatment of iron deficiency anaemia (IDA). In addition, the Company is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUGUBPBUPQUQM

(END) Dow Jones Newswires

September 07, 2016 02:37 ET (06:37 GMT)